Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

I am not clear on all of this and Helen and even her predecessors have not explaiined it in a way that can be easily understood (by me at least); but I'd think the partners (Roche, et. al) have a distinct incentive to keep the exclusivity granted by patent extensions, if only because they would need to go through another round of trials, with all of their uncertainties and costs, with a new bio-similar co-formula. I believe that was one of Helen's primary points. Again, it's not a clear subject for me and I'd like to have a lot more clarity on the whole topic, but I guess it'll have to come in dribs and drabs over time.